HSP90AA1 and hyperlipidemia: Network pharmacology research showed that MMP9, RELA, MMP2, PRKCA, HSP90AA1, and APP were major targets of CA for therapy of hyperlipidemia and thrombosis and may relate to pathways in cancer, estrogen signaling pathway, chemical carcinogenesis-receptor activation, and the AGE–RAGE signaling pathway in diabetic complications, etc. This investigation demonstrates the potential for CA as a hypolipidemic and antithrombotic drug candidate, offering a basis for exploring the action mechanism.